Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Shinde, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10641-10665
Closed Access | Times Cited: 11

Showing 11 citing articles:

An Analysis of Successful Hit-to-Clinical Candidate Pairs
Dean G. Brown
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7101-7139
Closed Access | Times Cited: 29
Molecular medicinal insights into scaffold hopping-based drug discovery success
Ayan Acharya, Mukul Yadav, Mithilesh Nagpure, et al.
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103845-103845
Closed Access | Times Cited: 26
SwissBioisostere 2021: updated structural, bioactivity and physicochemical data delivered by a reshaped web interface
Alessandro Cuozzo, Antoine Daina, Marta A. S. Perez, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. D1, pp. D1382-D1390
Open Access | Times Cited: 37
Serotonin Receptors as a Potential Target in the Treatment of Alzheimer’s Disease
Dmitrii V Eremin, Е. М. Кондаурова, Aleksander Ya Rodnyy, et al.
Biochemistry (Moscow) (2023) Vol. 88, Iss. 12-13, pp. 2023-2042
Closed Access | Times Cited: 10
Lead-Structure-Based Rigidization Approach to Optimize SirReal-Type Sirt2 Inhibitors
Matthias Frei, Thomas Wein, Franz Bracher
Molecules (2025) Vol. 30, Iss. 8, pp. 1728-1728
Open Access
The interaction between neurotransmitter receptor activity and amyloid-β pathology in Alzheimer's disease
Yuhan Nong, Jung Soo Kim, Jia Li, et al.
Journal of Alzheimer s Disease (2025)
Closed Access
Understanding How Physical Exercise Improves Alzheimer’s Disease: Cholinergic and Monoaminergic Systems
Boyi Zong, Fengzhi Yu, Xiaoyou Zhang, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 16
Dorsal raphe nucleus–hippocampus serotonergic circuit underlies the depressive and cognitive impairments in 5×FAD male mice
Meiqin Chen, Chenlu Wang, Yinan Lin, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling
Ramakrishna Nirogi, Grandhi Venkata Ramalingayya, Rajeshbabu Medapati, et al.
European Journal of Pharmacology (2023) Vol. 947, pp. 175625-175625
Closed Access | Times Cited: 2
Serotonin receptors - a potential target for the treatment of Alzheimer’s disease
D. Eremin, Е. М. Кондаурова, A. Ya Rodny, et al.
Биохимия (2023) Vol. 88, Iss. 12, pp. 2399-2421
Closed Access | Times Cited: 1
5-HT4R Modulators: A Patent Landscape
Patrick Dallemagne, Christophe Rochais
Pharmaceutical Patent Analyst (2021) Vol. 10, Iss. 4, pp. 179-181
Closed Access | Times Cited: 3
A selective and accurate liquid chromatography-tandem mass spectrometry method for the quantitation of the novel 5-HT4 receptor partial agonist SUVN-D4010 (Usmarapride) in human plasma and urine
Ramakrishna Nirogi, Ilayaraja Kalaikadhiban, Naga Surya Prakash Padala, et al.
Journal of Pharmaceutical and Biomedical Analysis (2022) Vol. 211, pp. 114617-114617
Closed Access | Times Cited: 1
Page 1

Scroll to top